about
Transient requirement of the PrrA-PrrB two-component system for early intracellular multiplication of Mycobacterium tuberculosisLive attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice.Bordetella pertussis filamentous hemagglutinin enhances the immunogenicity of liposome-delivered antigen administered intranasally.Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.Genital antibody responses in mice after intranasal infection with an attenuated candidate vector strain of Bordetella pertussis.Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infectionImmunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis.Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e.The French Connection: The First Large Population-Based Contact Survey in France Relevant for the Spread of Infectious Diseases.Bordetella pertussis from functional genomics to intranasal vaccination.Effect of maternal immune status on responsiveness of bacillus calmette-gurin vaccination in mouse neonates.The ins and outs of pertussis toxin.New pertussis vaccination approaches: en route to protect newborns?Live attenuated vaccines against pertussis.Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen.Distinct roles of the N-terminal and C-terminal precursor domains in the biogenesis of the Bordetella pertussis filamentous hemagglutinin.Live Attenuated Pertussis Vaccine BPZE1 Protects Baboons Against Bordetella pertussis Disease and Infection.Reciprocal interference of maternal and infant immunization in protection against pertussis.A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers.Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis.Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial.Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.Amino-terminal maturation of the Bordetella pertussis filamentous haemagglutinin.Human dendritic cell maturation and cytokine secretion upon stimulation with Bordetella pertussis filamentous haemagglutininDual mechanism of protection by live attenuated Bordetella pertussis BPZE1 against Bordetella bronchiseptica in miceAttenuated Bordetella pertussis: new live vaccines for intranasal immunisationPERISCOPE: road towards effective control of pertussisA mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infectionNasal Administration of Schistosoma mansoni Egg Antigen-Cholera B Subunit Conjugate Suppresses Hepatic Granuloma Formation and Reduces Mortality in S. mansoni-Infected MiceInteraction of Bordetella pertussis with mast cells, modulation of cytokine secretion by pertussis toxinIntranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in miceLocal transient induction of inflammatory cytokines after intranasal administration of recombinantBordetella pertussisEarly Protection against Pertussis Induced by Live Attenuated Bordetella pertussis BPZE1 Depends on TLR4
P50
Q28486444-5A2DCBCE-7F9A-4A58-9D9F-E20539C6AE15Q30819553-420A17B9-13BF-4889-8915-ABA6692A8906Q33725151-8A2C54A8-61EE-4B13-A63F-75D3CB0CAED8Q33752750-8729033F-9343-4E8B-82B9-7B5A6709B626Q33899407-16B89B7D-CAE6-4FD5-8541-83D91A4650C4Q34003167-8634243B-3114-413C-879D-4B240DA9909CQ34009193-E4A73002-506A-47FE-92A2-4939D2EC39CFQ34126969-CED1C96A-1D79-44C3-80A0-35EF6A80DF9CQ34650849-FD502AC4-CB16-46B8-ADCF-C0F8DABC2492Q35691952-DF7EF4B1-F829-4841-87AF-BC02BEEB8E6BQ35776252-B0DBD11B-6D0C-40B0-A5DE-E65BE70BA183Q37105797-0869988A-B163-48DD-8D29-D9B47A84ABD9Q37899279-ED005C9E-BD57-4205-8FCE-812806A1E715Q38009062-588CFA4B-14AA-422C-9BEE-2B3F88730BFCQ38236200-4F2585DF-5B07-4EBC-9737-52B616C50895Q39833195-3540204F-B4F9-4168-AA92-60F2216F9B9FQ39840301-A9F3A8B9-6A8C-429F-A224-DF754A5A5B0BQ40202103-C3CDF39E-8C24-4AED-A592-D993B2EB25BBQ40830016-DC4BA1D5-6489-4024-902B-2B77F6F7AC7BQ41860045-798490D5-CB77-41AE-8551-A769F592F7CDQ43604732-EA68F94A-B79E-4C61-B76B-3AC33F87E911Q43781170-9780CA5D-014B-4C6B-91CD-677395575D5AQ45233045-BF494399-B397-4B31-B795-626EBB4F4CF0Q50056769-E43D4178-0037-4C9D-8F7A-DC9D1BDBAA46Q54596792-1A8D61E7-74D0-4912-80DD-42925E07D524Q61766623-473FC14B-3874-458C-AEC6-DAA3535F623FQ61766626-E0674B86-31E7-4C7C-8C75-E5F26E6C80DDQ61766637-F4FCFB1E-3672-40E3-87E3-E4A49A620E12Q63370221-6138B56D-6DFE-4ED2-A432-8793257C3532Q63370226-B85EE726-B66A-4925-8410-B5FBB6EDA754Q63370228-3241C33B-96AF-4D56-80B9-8696FE5CF9DFQ63370231-7BE5A1B6-17B1-4859-AD3C-709813B77521Q63370234-9207E922-E3CB-4951-B898-C0C8FBCA54C1Q63370237-62D735B2-F6F9-487C-9FE1-85A17A07EAA7Q91302225-59C48260-1A12-4B41-842A-DAA987BD7124
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nathalie Mielcarek
@ast
Nathalie Mielcarek
@en
Nathalie Mielcarek
@es
Nathalie Mielcarek
@nl
type
label
Nathalie Mielcarek
@ast
Nathalie Mielcarek
@en
Nathalie Mielcarek
@es
Nathalie Mielcarek
@nl
prefLabel
Nathalie Mielcarek
@ast
Nathalie Mielcarek
@en
Nathalie Mielcarek
@es
Nathalie Mielcarek
@nl
P106
P21
P31
P496
0000-0002-5968-9442